Your session is about to expire
← Back to Search
Hormone Therapy
ORIC-101 for Prostate Cancer
Phase 1
Waitlist Available
Research Sponsored by Oric Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
one post-treatment tumor biopsy during Cycle 2
Must have been on treatment with enzalutamide for at least 3 months prior to documented evidence of PSA progression defined as per PCWG3: minimum of 2 rising values (3 measurements) obtained a minimum of one week apart with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of progression)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights
Study Summary
This trial is testing a new medication to see if it is safe and effective when used with a common prostate cancer drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You need to have a biopsy of your tumor after completing the second cycle of treatment.
Select...
You must have taken enzalutamide for at least 3 months before your PSA level showed signs of increasing. This increase should be confirmed by at least 2 rising values obtained a week apart, with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only sign of progression).
Select...
You are expected to live for at least 3 more months.
Select...
You have been diagnosed with a specific type of prostate cancer called adenocarcinoma.
Select...
You are currently taking enzalutamide for metastatic prostate cancer and your testosterone level is below 50 ng/dL.
Select...
Your platelet count is at least 100,000 per microliter.
Select...
You have not had a tumor biopsy while taking enzalutamide before joining this study.
Select...
You are in good physical condition and can perform daily activities without any major issues.
Select...
You have a white blood cell count of at least 1500 cells per cubic millimeter.
Select...
You may need to have a tumor biopsy at the end of treatment, but it's not required.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants with Abnormal 12-lead ECG
Number of Participants with Abnormal Laboratory Values
Number of Participants with Abnormal Vital Signs
+4 moreSecondary outcome measures
Area under the curve (AUC(0-24))
Circulating tumor cells (CTCs) conversion
Duration of response (DOR)
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Dose ExpansionExperimental Treatment2 Interventions
RP2D dose
Group II: Dose EscalationExperimental Treatment2 Interventions
ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ORIC-101
2018
Completed Phase 1
~60
Find a Location
Who is running the clinical trial?
Oric PharmaceuticalsLead Sponsor
3 Previous Clinical Trials
139 Total Patients Enrolled
ORIC PharmaceuticalsLead Sponsor
7 Previous Clinical Trials
549 Total Patients Enrolled
Pratik S. Multani, MDStudy DirectorORIC Pharmaceuticals
3 Previous Clinical Trials
181 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger